

What is claimed is:

1. A compound of Formula I



I

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the  group together with the N atom and the C atom to which it is attached forms a 5 membered ring, wherein the ring is aromatic, unsaturated, partially saturated, or saturated;

x, y, and z are independently selected from CR, CRR', N, NR'', O, $S(O)_n$, C=O, C=S, and C=NH;

each R and R' are independently selected from H, halogen, -OH, -CN, $–CO(C_{1-4}alkyl)$, $–S(O)_n(C_{1-4}alkyl)$, -COOH, $-COO(C_{1-4}alkyl)$, $-CONH_2$, $-CONH(C_{1-4}alkyl)$, $-CO(diC_{1-4}alkylamino)$, $-NH_2$, $C_{1-4}alkylamino$, $diC_{1-4}alkylamino$, $-NH(COC_{1-4}alkyl)$, $-N(C_{1-4}alkyl)C(=O)F$, $C_{1-4}alkyl$, $-(CH_2)_m(C_{3-5}cycloalkyl)$, $-CH_2(C_{3-5}heterocycloalkyl)$, $C_{1-4}deuteroalkyl$, $C_{3-5}cycloalkyl$, $C_{3-4}heterocycloalkyl$, $C_{2-4}alkenyl$, $C_{2-4}alkynyl$, $C_{1-4}alkoxy$, $C_{1-4}deuteroalkoxy$, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl;

wherein the $C_{1-4}alkyl$ group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, $C_{1-4}alkoxy$, $-NH_2$, $C_{1-4}alkylamino$, $diC_{1-4}alkylamino$, and $-S(O)_n(C_{1-4}alkyl)$;

wherein the $C_{1-4}alkoxy$ group is optionally substituted with 1 to 4 independently selected halogens or optionally substituted with a substituent selected from –OH, -CN, $C_{1-4}alkoxy$, $-NH_2$, $C_{1-4}alkylamino$, $diC_{1-4}alkylamino$, and $-S(O)_n(C_{1-4}alkyl)$;

wherein the $-CH_2(C_{3-5}cycloalkyl)$, $C_{3-4}heterocycloalkyl$, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4

substituents independently selected from halogen, –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkyl, -NH_2, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -$S(O)_n(C_{1-4}$alkyl); and


wherein R of a first CR or CRR' group and R of a second CR or CRR' group, if present, may together with the atoms to which they are attached, form a C_{3-5}carbocycle;


each R'' is independently selected from H, -OH, –$CO(C_{1-4}$alkyl), –$S(O)_n(C_{1-4}$alkyl), -$COO(C_{1-4}$alkyl), -$CONH_2$, -$CONH(C_{1-4}$alkyl), -$CO($diC_{1-4}alkylamino), C_{1-4}alkyl, -$(CH_2)_m(C_{3-5}$cycloalkyl), -$CH_2(C_{3-5}$heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl;


wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, -NH_2, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -$S(O)_n(C_{1-4}$alkyl); and

wherein the –$(CH_2)_m(C_{3-5}$cycloalkyl), C_{3-4}heterocycloalkyl, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkyl, -NH_2, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -$S(O)_n(C_{1-4}$alkyl);

R^1 is O, S, or NH;

R^2 is 

, 

, or 




, wherein

Ring A is a 5-membered heteroaryl containing one heteroatom selected from N, S, and O and optionally one or two further N atoms with the remaining ring atoms of the 5-membered heteroaryl being carbon, wherein

i) Ring A is attached via a C atom to the bicyclic core and R^3 is attached via an N atom; or

ii) Ring A is attached via an N atom to the bicyclic core and R^3 is attached via a C atom; or

iii) Ring A is attached via a C atom to the bicyclic core and R^3 is attached via a C atom;

and wherein the , , or  portion of R^2 is further optionally substituted with one or two independently selected substituents $R^{3'}$;




R^3 is C_{1-6}alkyl, C_{3-5}cycloalkyl, C_{2-6}alkoxy, C_{1-6}alkylamino, diC_{1-6}alkylamino, -$S(O)_n(C_{1-6}$alkyl), -$CH_2(C_{3-5}$cycloalkyl), -$OCH_2(C_{3-5}$cycloalkyl), -$NHCH_2(C_{3-5}$cycloalkyl), -$S(O)_nCH_2(C_{3-5}$cycloalkyl), -$CH_2(C_{3-5}$heterocycloalkyl), or phenyl; wherein the C_{1-6}alkyl, C_{3-5}cycloalkyl, C_{2-6}alkoxy, C_{1-6}alkylamino, diC_{1-6}alkylamino, -$S(O)_n(C_{1-6}$alkyl), -$CH_2(C_{3-5}$cycloalkyl), -$OCH_2(C_{3-5}$cycloalkyl), -$NHCH_2(C_{3-5}$cycloalkyl), and -$S(O)_nCH_2(C_{3-5}$cycloalkyl) groups are optionally substituted with 1-9 halogen atoms and are optionally substituted with –CN and wherein the phenyl is optionally substituted with 1-3 substituents selected from halogen, C_{1-4}alkyl, C_{1-4}haloalkyl, C_{1-4}alkoxy, and C_{1-4}haloalkoxy;




$R^{3'}$ is independently halogen, C_{1-4}alkyl, C_{1-4}haloalkyl, C_{1-4}alkoxy, or C_{1-4}haloalkoxy;





R^4 is C_{1-3}alkyl, C_{1-4}haloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkoxy, C_{3-5}cycloalkyl, or C_{3-5}cyclohaloalkyl;

n is 0, 1, or 2; and

m is 1 or 2; provided that

(1) if  is  then R^2 is not ;

(2) if  is  then R^2 is not ;

(3) if  is  or  then R^2 is not ; and

(4) if any of R, R' or R'' is phenyl then R^3 is not an unsubstituted C_{1-6}alkyl and R^3 is not C_{1-2}alkoxy.

2. The compound according to Claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound is not

1,3,3-trimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,2H,3H,5H-imidazo[1,2-a]pyrimidine-2,5-dione;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(pyrimidin-5-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one; or

2-[(methylamino)methyl]-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one.


3. The compound according to Claim 1 or Claim 2, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

x, y, and z are independently selected from CR, N, ~~and~~ NR'', and S.


~~4. The compound according to Claim 1 or Claim 2, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein~~

~~x, y, and z are independently selected from CR, N, and S.~~


~~5.~~4. The compound according to Claim 1 or Claim 2, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein



6.5. The compound according to Claim 1 or Claim 2, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein



7.6. The compound according to Claim 1 or Claim 2, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein



8.7. The compound according to any one of Claims 1-667, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R and R', if present, are independently selected from H, halogen, -COO(C_{1-4}alkyl), C_{1-4}alkyl, -$(CH_2)_m$(C_{3-5}cycloalkyl), -CH_2(C_{3-5}heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkynyl, C_{1-4}alkoxy, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkylamino, and diC_{1-4}alkylamino; and

wherein the $–(CH_2)_m(C_{3-5}$cycloalkyl), 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, and C_{1-4}alkyl.

~~9.~~8. The compound according to any one of Claims 1-~~6~~7, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R and R', if present, are independently selected from H, halogen, C_{1-4}alkyl, C_{1-4}deuteroalkyl, and C_{1-4}alkoxy; wherein the C_{1-4}alkyl group is optionally substituted with a substituent selected from –OH and -CN.

~~10.~~9. The compound according to any one of Claims 1-~~6~~7, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R and R', if present, are independently selected from H and C_{1-4}alkyl.

~~11. The compound according to any one of Claims 1-7, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein~~

~~each R and R', if present, are independently selected from H, F, Cl, -COOMe, methyl, ethyl, isopropyl, fluoromethyl, trifluoromethyl, $-CH_2OH$, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl, $-CH_2CN$, 2-hydroxypropyl, $-CH_2OCH_3$, $-CH_2CH_2OCH_3$, methylaminomethyl, dimethylaminomethyl, 2-(dimethylamino)ethyl, cyclopropylmethyl, (2,2-difluorocyclopropyl)methyl, (3,3-difluorocyclobutyl)methyl, (1-hydroxycyclopropyl)ethyl, $-CD_3$, cyclopropyl, (oxetan-3-yl)methyl, oxetan-3-yl, prop-2-yn-1-yl, methoxy, phenyl, pyrazolyl, 1-methyl-pyrazol-4-yl, pyridinyl, pyrazinyl, pyrimidinyl, 6-methylpyridin-2-yl, and 6-chloropyridin-2-yl.~~

~~12.~~10. The compound according to any one of Claims 1-~~6~~7, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R and R', if present, are independently selected from H, Cl, methyl, $-CH_2OH$, 2-hydroxyethyl, $-CH_2CN$, $-CD_3$, and methoxy.

13. The compound according to any one of Claims 1-7, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R and R', if present, are independently selected from H and methyl.

14. The compound according to any one of Claims 1-13, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R'', if present, is independently selected from H, -COO(C_{1-4}alkyl), C_{1-4}alkyl, -$(CH_2)_m$(C_{3-5}cycloalkyl), -CH_2(C_{3-5}heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkynyl, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from -OH, -CN, C_{1-4}alkoxy, C_{1-4}alkylamino, and diC_{1-4}alkylamino; and

wherein the -$(CH_2)_m$(C_{3-5}cycloalkyl), 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, -OH, and C_{1-4}alkyl.

15. The compound according to any one of Claims 1-13, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R'', if present, is independently selected from H, C_{1-4}alkyl, and C_{1-4}deuteroalkyl; wherein the C_{1-4}alkyl group is optionally substituted with a substituent selected from -OH and -CN.

16. The compound according to any one of Claims 1-13, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R'', if present, is independently selected from H and C_{1-4}alkyl.

17. The compound according to any one of Claims 1-13, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R'', if present, is independently selected from H, -COOMe, methyl, ethyl, isopropyl, fluoromethyl, trifluoromethyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl, -CH_2CN, 2-hydroxypropyl, -CH_2OCH_3, -$CH_2CH_2OCH_3$, dimethylaminomethyl, 2-(dimethylamino)ethyl, cyclopropylmethyl, (2,2-difluorocyclopropyl)methyl, (3,3-

~~difluorocyclobutyl)methyl, (1-hydroxycyclopropyl)ethyl, CD_3, cyclopropyl, (oxetan-3-yl)methyl, oxetan-3-yl, prop-2-yn-1-yl, phenyl, pyrazolyl, 1-methyl pyrazol-4-yl, pyridinyl, pyrazinyl, pyrimidinyl, 6-methylpyridin-2-yl, and 6-chloropyridin-2-yl.~~

~~18. The compound according to any one of Claims 1-13, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein each R'', if present, is independently selected from H, methyl, 2-hydroxyethyl, CH_2CN, and CD_3.~~

~~19. The compound according to any one of Claims 1-13, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein each R'', if present, is independently selected from H and methyl.~~

~~20. The compound according to any one of Claims 1-19, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein R of a first CR or CRR' group and R of a second CR or CRR' group, if present, together with the atoms to which they are attached, form a cyclopropyl.~~


~~21.~~11. The compound according to any one of Claims 1-~~12~~10, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^1 is O or S.


~~22.~~12. The compound according to any one of Claims 1-~~10~~20, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^1 is O.


~~23.~~13. The compound according to any one of Claims 1-12~~22~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^2 is .

~~24.~~14. The compound according to any one of Claims 1-12~~22~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^2 is .

~~25.~~15. The compound according to any one of Claims 1-12~~22~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein



R^2 is , wherein A is a 5-membered heteroaryl containing two N atoms.

~~26.~~16. The compound according to any one of Claims 1-12~~22~~, 14~~24~~, and 15~~25~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein A is attached via a C atom to the bicyclic core and R^3 is attached via an N atom.


~~27. The compound according to any one of Claims 1-22, 24, and 25, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein A is attached via an N atom to the bicyclic core and R^3 is attached via an C atom.~~

~~28. The compound according to any one of Claims 1-22, 24, and 25, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein A is attached via a C atom to the bicyclic core and R^3 is attached via a C atom.~~




~~29.~~17. The compound according to any one of Claims 1-12~~22~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein




R^2 is  or .




~~30.~~18. The compound according to any one of Claims 1-12~~22~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^2 is .

~~31. The compound according to any one of Claims 1-30, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the~~

~~, , or  portion of R^2 is not further optionally substituted with one or two independently selected substituents $R^{3'}$.~~

~~32. The compound according to any one of Claims 1-30, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the , , or  portion of R^2 is substituted with one or two independently selected substituents $R^{3'}$.~~

~~33. The compound according to any one of Claims 1-33, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the , , or  portion of R^2 is substituted with one substituent $R^{3'}$.~~

~~34.~~19. The compound according to any one of Claims 1-~~33~~18, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^3 is $C_{1\text{-}6}$alkyl, $C_{2\text{-}6}$alkoxy, -CH_2($C_{3\text{-}5}$cycloalkyl), -OCH_2($C_{3\text{-}5}$cycloalkyl), -CH_2($C_{3\text{-}5}$heterocycloalkyl), or phenyl; wherein the $C_{1\text{-}6}$alkyl, $C_{2\text{-}6}$alkoxy, -CH_2($C_{3\text{-}5}$cycloalkyl), and -OCH_2($C_{3\text{-}5}$cycloalkyl) groups are optionally substituted with 1-9 halogen atoms and are optionally substituted with –CN and wherein the phenyl is optionally substituted with one halogen substituent.

~~35.~~20. The compound according to any one of Claims 1-18~~33~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^3 is $C_{1\text{-}6}$alkyl, $C_{2\text{-}6}$alkoxy, -CH_2($C_{3\text{-}5}$cycloalkyl), or -CH_2($C_{3\text{-}5}$heterocycloalkyl); wherein the $C_{1\text{-}6}$alkyl, $C_{2\text{-}6}$alkoxy, and -CH_2($C_{3\text{-}5}$cycloalkyl) groups are optionally substituted with 1-9 halogen atoms.

~~36. The compound according to any one of Claims 1-33, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein~~

~~R^3 is C_{1-6}alkyl, C_{2-6}alkoxy, $-CH_2(C_{3-5}$cycloalkyl), or $-CH_2(C_{3-5}$heterocycloalkyl); wherein the C_{1-6}alkyl, C_{2-6}alkoxy, and $-CH_2(C_{3-5}$cycloalkyl) groups are substituted with 2-5 halogen atoms.~~

~~37. The compound according to any one of Claims 1-33, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein~~

~~R^3 is 2,2,2-trifluoroethyl, propyl, 2,2-difluoropropyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, 2,2,3,3,3-pentafluoropropyl, $-OCH_2CN$, $-OC(CH_3)_2CN$, difluoromethoxy, trifluoromethoxy, $-OCH(CN)CH_3$, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2,2-difluoropropoxy, 2,2,3,3-tetrafluoropropoxy, 2,2,3,3,3-pentafluoropropoxy, cyclopropylmethyl, (2,2-difluorocyclopropyl)methyl, (3,3-difluorocyclobutyl)methyl, cyclopropylmethoxy, (2,2-difluorocyclopropyl)methoxy, (oxetan-3-yl)methyl, phenyl, 3-fluorophenyl, or 4-fluorophenyl.~~

~~38.~~21. The compound according to any one of Claims 1-18~~33~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^3 is 3,3,3-trifluoropropyl, 2,2,3,3,3-pentafluoropropyl, 2,2,2-trifluoroethoxy, or (2,2-difluorocyclopropyl)methyl.

~~39.~~22. The compound according to any one of Claims 1-21~~30 and 32-38~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

$R^{3'}$ is independently halogen or C_{1-4}alkyl.

~~40. The compound according to any one of Claims 1-30 and 32-38, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein~~

~~$R^{3'}$ is independently F or methyl.~~

~~41.~~23. The compound according to any one of Claims 1-22~~40~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^4 is C_{1-3}alkyl, C_{1-4}haloalkyl, C_{1-4}alkoxy, or C_{3-5}cycloalkyl.

~~42.~~24. The compound according to any one of Claims 1-22~~40~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^4 is C_{1-4}haloalkyl.

~~43. The compound according to any one of Claims 1-40, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein~~

~~R^4 is methyl, ethyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, or cyclopropyl.~~

~~44. The compound according to any one of Claims 1-40, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein~~

~~R^4 is trifluoromethyl.~~

~~45.~~25. The compound according to any one of Claims 1-24~~44~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

n is 0.

~~46. The compound according to any one of Claims 1-44, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein~~

~~n is 1.~~

~~47. The compound according to any one of Claims 1-44, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein~~

~~n is 2.~~

~~48. The compound according to any one of Claims 1-47, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein~~

~~m is 1.~~

~~49. The compound according to any one of Claims 1-47, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein~~

~~m is 2.~~

~~50.~~26. The compound according to Claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound is

6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,2H,3H,5H-imidazo[1,2-a]pyrimidine-2,5-dione;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

3-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-3,7-bis(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

2-fluoro-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

2-chloro-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

2-(methoxymethyl)-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-cyclopropyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-cyclopropyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2,3-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5-(trifluoromethyl)-3H,7H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one;

2,3-dimethyl-5-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-3H,7H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one;

7-ethyl-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5-(trifluoromethyl)-1H,7H-pyrazolo[1,5-a]pyrimidin-7-one;

1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5-(trifluoromethyl)-1H,7H-pyrazolo[1,5-a]pyrimidin-7-one;

1,3-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5-(trifluoromethyl)-1H,7H-pyrazolo[1,5-a]pyrimidin-7-one;

3-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-2-(trifluoromethyl)-4H,6H,7H,8H-pyrrolo[1,2-a]pyrimidin-4-one;

2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-(trifluoromethyl)-3-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-4H,6H,7H,8H-pyrrolo[1,2-a]pyrimidin-4-one;

6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-2H,3H,5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

6-{1-[(2,2-difluorocyclopropyl)methyl]-1H-pyrazol-4-yl}-2-methyl-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-2H,3H,5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

8-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-9-(trifluoromethyl)-6,10-diazatricyclo[4.4.0.0^{2,4}]deca-1(10),8-dien-7-one;

6-{1-[(3,3-difluorocyclobutyl)methyl]-1H-pyrazol-4-yl}-2-methyl-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-[1,2,4]triazolo[4,3-a]pyrimidin-5-one;

3-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5-(trifluoromethyl)-3H,7H-[1,2,3,4]tetrazolo[1,5-a]pyrimidin-7-one;

2-methyl-6-{1-[(oxetan-3-yl)methyl]-1H-pyrazol-4-yl}-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-3-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

2-(hydroxymethyl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

2-(hydroxymethyl)-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

2-chloro-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(propan-2-yl)-7-(trifluoromethyl)-1H,2H,3H,5H-imidazo[1,2-a]pyrimidine-2,5-dione;

1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

3-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5-(trifluoromethyl)-3H,7H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3]oxazolo[3,2-a]pyrimidin-5-one;

2-methyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

7-ethoxy-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-(methoxymethyl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-methoxy-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

3-chloro-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-(hydroxymethyl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-(hydroxymethyl)-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,2H,3H,5H-imidazo[1,2-a]pyrimidine-2,5-dione;

2-chloro-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-chloro-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-cyclopropyl-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-chloro-1-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-(methoxymethyl)-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-ethyl-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(2-methoxyethyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(propan-2-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-{1-[(2,2-difluorocyclopropyl)methyl]-1H-pyrazol-4-yl}-1,2-dimethyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-{1-[(3,3-difluorocyclobutyl)methyl]-1H-pyrazol-4-yl}-1,2-dimethyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-[1-(cyclopropylmethyl)-1H-pyrazol-4-yl]-1,2-dimethyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(cyclopropylmethyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-(methoxymethyl)-1-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(2-hydroxypropyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-{1-[(oxetan-3-yl)methyl]-1H-pyrazol-4-yl}-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(cyclopropylmethyl)-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-[2-(dimethylamino)ethyl]-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(cyclopropylmethyl)-2-methyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-[2-(dimethylamino)ethyl]-2-methyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-3-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methoxy-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methoxy-1-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-{1-[(2,2-difluorocyclopropyl)methyl]-1H-pyrazol-4-yl}-2-methyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-($^2H_3$)methyl-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-($^2H_3$)methyl-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(2-hydroxyethyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

methyl 2-methyl-5-oxo-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidine-1-carboxylate;

1-[(2,2-difluorocyclopropyl)methyl]-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-[(3,3-difluorocyclobutyl)methyl]-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(2-hydroxyethyl)-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-[2-(dimethylamino)ethyl]-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(prop-2-yn-1-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-{2-methyl-5-oxo-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-1-yl}acetonitrile;

2-[2-methyl-5-oxo-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-1-yl]acetonitrile;

1-(2-hydroxy-2-methylpropyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-[2-(1-hydroxycyclopropyl)ethyl]-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-1-[(oxetan-3-yl)methyl]-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-1-(oxetan-3-yl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidine-5-thione;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(pyridin-2-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-1-(pyridin-2-yl)-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(pyrazin-2-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-1-(6-methylpyridin-2-yl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(pyridin-3-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-phenyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(6-chloropyridin-2-yl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(pyridin-4-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(1H-pyrazol-4-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-(fluoromethyl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-[(dimethylamino)methyl]-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

6-(1-{[(1R)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-(1-{[(1S)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-(1-{[(1R)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-1,2-dimethyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-(1-{[(1S)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-1,2-dimethyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-(1-{[(1R)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

6-(1-{[(1S)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

(2R)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-2H,3H,5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

(2S)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-2H,3H,5H,6H,7H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

1-{[(1R)-2,2-difluorocyclopropyl]methyl}-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one; or

1-{[(1S)-2,2-difluorocyclopropyl]methyl}-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one.

~~51.~~27. The compound according to Claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound is

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-methoxy-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-(hydroxymethyl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-chloro-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-($^{2}H_3$)methyl-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(2-hydroxyethyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;



2-{2-methyl-5-oxo-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-1-yl}acetonitrile;


2-[2-methyl-5-oxo-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-1-yl]acetonitrile;

6-(1-{[(1R)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one; or


6-(1-{[(1S)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one.

~~52.~~28. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:




, , and


.











~~53. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is~~


~~.~~



~~54. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is~~



~~.~~

~~55.~~29. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:













5




, , and


.


~~56. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is~~


~~.~~


~~57. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is~~


~~.~~


58. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is



59. The compound according to Claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound is




60. The compound according to Claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound is




61. The compound according to Claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound


~~is~~




~~62. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is~~




~~63. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is~~




~~64. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is~~




~~65. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is~~




~~66. The compound according to Claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound is~~



~~67. The compound according to Claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound is~~



30. A compound of Formula I-1



I-1

wherein

X is H or Br;

R^1 is O, S, or NH; and


R is H, F, Cl, -OH, -CN, –CO(C_{1-4}alkyl), –S(O)$_n$(C_{1-4}alkyl), -COOH, -COO(C_{1-4}alkyl), -CONH$_2$, -CONH(C_{1-4}alkyl), -CO(diC_{1-4}alkylamino), -NH(COC_{1-4}alkyl), -N(C_{1-4}alkyl)C(=O)F, C_{1-4}alkyl, -(CH$_2$)$_m$(C_{3-5}cycloalkyl), -CH$_2$(C_{3-5}heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}deuteroalkoxy, 5-membered heteroaryl, or 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl);

wherein the C_{1-4}alkoxy group is optionally substituted with 1 to 4 independently selected halogens or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl); and

wherein the -CH$_2$(C_{3-5}cycloalkyl), C_{3-4}heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkyl, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl).

31. A compound of Formula I-2



I-2

or a tautomer thereof, wherein

X is H or Br;

R^1 is O, S, or NH;

R is H, halogen, -OH, -CN, –CO(C_{1-4}alkyl), –S(O)$_n$(C_{1-4}alkyl), -COOH, -COO(C_{1-4}alkyl), -CONH$_2$, -CONH(C_{1-4}alkyl), -CO(diC_{1-4}alkylamino), -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, -NH(COC_{1-4}alkyl), -N(C_{1-4}alkyl)C(=O)F, C_{1-4}alkyl, -(CH$_2$)$_m$(C_{3-5}cycloalkyl), -

$CH_2(C_{3-5}$heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}deuteroalkoxy, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, $-NH_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and $-S(O)_n(C_{1-4}$alkyl);

wherein the C_{1-4}alkoxy group is optionally substituted with 1 to 4 independently selected halogens or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, $-NH_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and $-S(O)_n(C_{1-4}$alkyl); and

wherein the $-CH_2(C_{3-5}$cycloalkyl), C_{3-4}heterocycloalkyl, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkyl, $-NH_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and $-S(O)_n(C_{1-4}$alkyl); and


R'' is H, 2-trimethylsilylethoxymethyl, -OH, $-CO(C_{1-4}$alkyl), $-S(O)_n(C_{1-4}$alkyl), $-COO(C_{1-4}$alkyl), $-CONH_2$, $-CONH(C_{1-4}$alkyl), $-CO($diC_{1-4}alkylamino), C_{1-4}alkyl, $-(CH_2)_m(C_{3-5}$cycloalkyl), $-CH_2(C_{3-5}$heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, phenyl, 5-membered heteroaryl, or 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, $-NH_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and $-S(O)_n(C_{1-4}$alkyl); and

wherein the $-(CH_2)_m(C_{3-5}$cycloalkyl), C_{3-4}heterocycloalkyl, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkyl, $-NH_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and $-S(O)_n(C_{1-4}$alkyl);




with the proviso that if X is H and R'' is not 2-trimethylsilylethoxymethyl, then R is not H, C_{1-4}alkyl, or phenyl.

32. A compound of Formula I



I

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer,

wherein  is  or ;

each instance of R is independently selected from H, halogen, -OH, -CN, –CO(C_{1-4}alkyl), –S(O)$_n$(C_{1-4}alkyl), -COOH, -COO(C_{1-4}alkyl), -CONH$_2$, -CONH(C_{1-4}alkyl), -CO(diC_{1-4}alkylamino), -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, -NH(COC$_{1-4}$alkyl), -N(C_{1-4}alkyl)C(=O)F, C_{1-4}alkyl, -(CH$_2$)$_m$(C_{3-5}cycloalkyl), -CH$_2$(C_{3-5}heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}deuteroalkoxy, 5-membered heteroaryl, and 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F atoms or is optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl);

wherein the C_{1-4}alkoxy group is optionally substituted with 1 to 4 independently selected halogens or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl);

wherein the -CH$_2$(C_{3-5}cycloalkyl), C_{3-4}heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkyl, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl); and




wherein R of a first CR group and R of a second CR group, if present, may, together with the atoms to which they are attached, form a C_{3-5}carbocycle;

each R'', if present, is independently selected from H, -OH, –CO(C_{1-4}alkyl), –S(O)$_n$(C_{1-4}alkyl), -COO(C_{1-4}alkyl), -CONH$_2$, -CONH(C_{1-4}alkyl), -CO(diC_{1-4}alkylamino), C_{1-4}alkyl, -(CH$_2$)$_m$(C_{3-5}cycloalkyl), -CH$_2$(C_{3-5}heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, 5-membered heteroaryl, and 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F atoms or is optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl); and

wherein the –(CH$_2$)$_m$(C_{3-5}cycloalkyl), C_{3-4}heterocycloalkyl, 5-membered heteroaryl, or 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkyl, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl);

R^1 is O, S, or NH;




R^2 is , , or , wherein

Ring A is a 5-membered heteroaryl containing one heteroatom selected from N, S, and O and optionally one or two further N atoms with the remaining ring atoms of the 5-membered heteroaryl being carbon, wherein

iv) Ring A is attached via a C atom to the bicyclic core and R^3 is attached via an N atom; or

v) Ring A is attached via an N atom to the bicyclic core and R^3 is attached via a C atom; or

vi) Ring A is attached via a C atom to the bicyclic core and R^3 is attached via a C atom;

and wherein the , , or  portion of R^2 is further optionally substituted with one or two independently selected substituents $R^{3'}$;

R^3 is C_{1-6}alkyl, C_{3-5}cycloalkyl, C_{2-6}alkoxy, C_{1-6}alkylamino, diC_{1-6}alkylamino, -S(O)$_n$(C_{1-6}alkyl), -CH$_2$(C_{3-5}cycloalkyl), -OCH$_2$(C_{3-5}cycloalkyl), -NHCH$_2$(C_{3-5}cycloalkyl), -

$S(O)_nCH_2(C_{3-5}$cycloalkyl), $-CH_2(C_{3-5}$heterocycloalkyl), or phenyl; wherein the C_{1-6}alkyl, C_{3-5}cycloalkyl, C_{2-6}alkoxy, C_{1-6}alkylamino, diC_{1-6}alkylamino, $-S(O)_n(C_{1-6}$alkyl), $-CH_2(C_{3-5}$cycloalkyl), $-OCH_2(C_{3-5}$cycloalkyl), $-NHCH_2(C_{3-5}$cycloalkyl), and $-S(O)_nCH_2(C_{3-5}$cycloalkyl) groups are optionally substituted with 1-9 halogen atoms and are optionally substituted with –CN and wherein the phenyl is optionally substituted with 1-3 substituents selected from halogen, C_{1-4}alkyl, C_{1-4}haloalkyl, C_{1-4}alkoxy, and C_{1-4}haloalkoxy;

$R^{3'}$, if present, is independently halogen, C_{1-4}alkyl, C_{1-4}haloalkyl, C_{1-4}alkoxy, or C_{1-4}haloalkoxy;

R^4 is C_{1-3}alkyl, C_{1-4}haloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkoxy, C_{3-5}cycloalkyl, or C_{3-5}cyclohaloalkyl;

n is 0, 1, or 2; and

m is 1 or 2.

33. The compound according to Claim 32, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R is independently selected from H, halogen, $-COO(C_{1-4}$alkyl), C_{1-4}alkyl, $-(CH_2)_m(C_{3-5}$cycloalkyl), $-CH_2(C_{3-5}$heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkynyl, C_{1-4}alkoxy, 5-membered heteroaryl, and 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F atoms or is optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkylamino, and diC_{1-4}alkylamino; and

wherein the $-(CH_2)_m(C_{3-5}$cycloalkyl), 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, and C_{1-4}alkyl.

34. The compound according to Claim 32, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R is independently selected from H, halogen, $-COO(C_{1-4}$alkyl), C_{1-4}alkyl, $-(CH_2)_m(C_{3-5}$cycloalkyl), $-CH_2(C_{3-5}$heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-}

$_4$heterocycloalkyl, C_{2-4}alkynyl, C_{1-4}alkoxy, 5-membered heteroaryl, and 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F atoms or is optionally substituted with a substituent selected from –OH, -CN, and C_{1-4}alkoxy.

35. The compound according to Claim 32, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R is independently selected from H, C_{1-4}alkyl, C_{1-4}deuteroalkyl, and C_{1-4}alkoxy; wherein the C_{1-4}alkyl group is optionally substituted with a substituent selected from –OH and -CN.

36. The compound according to Claim 32, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein each R is independently selected from H and methyl.

37. The compound according to any one of Claims 32 to 36, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R'', if present, is independently selected from H, -COO(C_{1-4}alkyl), C_{1-4}alkyl, -$(CH_2)_m$(C_{3-5}cycloalkyl), -CH_2(C_{3-5}heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkynyl, 5-membered heteroaryl, and 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkylamino, and diC_{1-4}alkylamino; and


wherein the –$(CH_2)_m$(C_{3-5}cycloalkyl), 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, and C_{1-4}alkyl.


38. The compound according to any one of Claims 32 to 36, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein


each R'', if present, is independently selected from H, -COOMe, methyl, ethyl, isopropyl, fluoromethyl, trifluoromethyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl, -CH_2CN, 2-hydroxypropyl, -CH_2OCH_3, -$CH_2CH_2OCH_3$, dimethylaminomethyl, 2-



(dimethylamino)ethyl, cyclopropylmethyl, (2,2-difluorocyclopropyl)methyl, (3,3-difluorocyclobutyl)methyl, (1-hydroxycyclopropyl)ethyl, -CD_3, cyclopropyl, (oxetan-3-yl)methyl, oxetan-3-yl, prop-2-yn-1-yl, pyrazolyl, 1-methyl-pyrazol-4-yl, pyridinyl, pyrazinyl, pyrimidinyl, 6-methylpyridin-2-yl, and 6-chloropyridin-2-yl.

39. The compound according to any one of Claims 32 to 38, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein R^1 is O.


40. The compound according to any one of Claims 32 to 39, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein R^2 is .

41. The compound according to any one of Claims 32 to 39, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein R^2 is .

42. The compound according to any one of Claims 32 to 39, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein R^2 is , wherein A is a 5-membered heteroaryl containing two N atoms.

43. The compound according to any one of Claims 32 to 39, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein R^2 is  or .

44. The compound according to any one of Claims 32 to 39, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^2 is  .

45. The compound according to any one of Claims 32 to 44, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein R^3 is C_{1-6}alkyl, C_{2-6}alkoxy, -CH_2(C_{3-5}cycloalkyl), -OCH_2(C_{3-5}cycloalkyl), -CH_2(C_{3-5}heterocycloalkyl), or phenyl; wherein the C_{1-6}alkyl, C_{2-6}alkoxy, -CH_2(C_{3-5}cycloalkyl), and -OCH_2(C_{3-5}cycloalkyl) groups are optionally substituted with 1-9 halogen atoms and are optionally substituted with –CN and wherein the phenyl is optionally substituted with one halogen substituent.

46. The compound according to any one of Claims 32 to 44, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein R^3 is 2,2,2-trifluoroethyl, propyl, 2,2-difluoropropyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, 2,2,3,3,3-pentafluoropropyl, -OCH_2CN, -$OC(CH_3)_2CN$, difluoromethoxy, trifluoromethoxy, -$OCH(CN)CH_3$, 2-fluoroethoxy, 2,2,-difluoroethoxy, 2,2,2-trifluoroethoxy, 2,2-difluoropropoxy, 2,2,3,3-tetrafluoropropoxy, 2,2,3,3,3-pentafluoropropoxy, cyclopropylmethyl, (2,2-difluorocyclopropyl)methyl, (3,3-difluorocyclobutyl)methyl, cyclopropylmethoxy, (2,2-difluorocyclopropyl)methoxy, (oxetan-3-yl)methyl, phenyl, 3-fluorophenyl, or 4-fluorophenyl.

47. The compound according to any one of Claims 32 to 44, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein R^3 is C_{1-6}alkyl, C_{2-6}alkoxy, -CH_2(C_{3-5}cycloalkyl), or -CH_2(C_{3-5}heterocycloalkyl); wherein the C_{1-6}alkyl, C_{2-6}alkoxy, and -CH_2(C_{3-5}cycloalkyl) groups are substituted with 2-5 halogen atoms.

48. The compound according to any one of Claims 32 to 47, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein R^4 is C_{1-3}alkyl, C_{1-4}haloalkyl, C_{1-4}alkoxy, or C_{3-5}cycloalkyl.

49. The compound according to any one of Claims 32 to 47, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein R^4 is C_{1-4}haloalkyl.

50. The compound according to any one of Claims 32 to 47, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein R^4 is methyl, ethyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, or cyclopropyl.

51. The compound according to Claim 32, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound is

1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

3-chloro-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-chloro-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-chloro-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-cyclopropyl-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-chloro-1-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-(methoxymethyl)-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-ethyl-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(2-methoxyethyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(propan-2-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-{1-[(2,2-difluorocyclopropyl)methyl]-1H-pyrazol-4-yl}-1,2-dimethyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-{1-[(3,3-difluorocyclobutyl)methyl]-1H-pyrazol-4-yl}-1,2-dimethyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-[1-(cyclopropylmethyl)-1H-pyrazol-4-yl]-1,2-dimethyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(cyclopropylmethyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-(methoxymethyl)-1-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(2-hydroxypropyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-{1-[(oxetan-3-yl)methyl]-1H-pyrazol-4-yl}-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(cyclopropylmethyl)-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-[2-(dimethylamino)ethyl]-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(cyclopropylmethyl)-2-methyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-[2-(dimethylamino)ethyl]-2-methyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-3-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methoxy-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methoxy-1-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-{1-[(2,2-difluorocyclopropyl)methyl]-1H-pyrazol-4-yl}-2-methyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-($^{2}H_{3}$)methyl-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-($^{2}H_{3}$)methyl-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(2-hydroxyethyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

methyl 2-methyl-5-oxo-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidine-1-carboxylate;

1-[(2,2-difluorocyclopropyl)methyl]-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-[(3,3-difluorocyclobutyl)methyl]-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(2-hydroxyethyl)-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-[2-(dimethylamino)ethyl]-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(prop-2-yn-1-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-{2-methyl-5-oxo-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-1-yl}acetonitrile;

2-[2-methyl-5-oxo-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-1-yl]acetonitrile;

1-(2-hydroxy-2-methylpropyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-[2-(1-hydroxycyclopropyl)ethyl]-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-1-[(oxetan-3-yl)methyl]-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-1-(oxetan-3-yl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidine-5-thione;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(pyridin-2-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-1-(pyridin-2-yl)-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(pyrazin-2-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-1-(6-methylpyridin-2-yl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(pyridin-3-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(6-chloropyridin-2-yl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(pyridin-4-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(1H-pyrazol-4-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-(1-{[(1R)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-(1-{[(1S)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-(1-{[(1R)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-1,2-dimethyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-(1-{[(1S)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-1,2-dimethyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-{[(1R)-2,2-difluorocyclopropyl]methyl}-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one; or

1-{[(1S)-2,2-difluorocyclopropyl]methyl}-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one.

52. The compound according to Claim 32, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound is

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-(methoxymethyl)-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-cyclopropyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-cyclopropyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

7-ethyl-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

6-{1-[(2,2-difluorocyclopropyl)methyl]-1H-pyrazol-4-yl}-2-methyl-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

6-{1-[(3,3-difluorocyclobutyl)methyl]-1H-pyrazol-4-yl}-2-methyl-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-methyl-6-{1-[(oxetan-3-yl)methyl]-1H-pyrazol-4-yl}-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-3-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-methyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

7-ethoxy-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-(methoxymethyl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-methoxy-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-(hydroxymethyl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-(hydroxymethyl)-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;


2-(fluoromethyl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-[(dimethylamino)methyl]-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

6-(1-{[(1R)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one; or


6-(1-{[(1S)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one.

53. The compound according to Claim 32, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

54. The compound according to Claim 32, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

55. The compound according to Claim 32, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

56. The compound according to Claim 32, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

57. The compound according to Claim 32, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

58. The compound according to Claim 32, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

59. The compound according to Claim 32, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

60. The compound according to Claim 32, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

61. The compound according to Claim 32, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

62. The compound according to Claim 32, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

63. The compound according to Claim 32, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

64. The compound according to Claim 32, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

65. The compound according to Claim 32, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

66. The compound according to Claim 32, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

67. The compound according to Claim 32, or a pharmaceutically acceptable salt thereof, wherein the compound is



.

68. The compound according to Claim 32, or a pharmaceutically acceptable salt thereof, wherein the compound is



.

~~68.~~69. A pharmaceutical composition comprising the compound according to any one of Claims 1-68~~67~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, and a pharmaceutically acceptable excipient.

~~69.~~70. A compound according to any one of Claims 1-~~67~~68, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim ~~68~~ 69 for use ~~as a medicament~~in therapy.

~~70.~~71. Use of a ~~A~~ compound according to any one of Claims 1-68~~67~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 69~~68~~ in the manufacturing of medicament for ~~for use in~~ reducing ~~the~~ body weight ~~of a subject~~.

~~71.~~72. Use of a ~~A~~ compound according to any one of Claims 1-68~~67~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 69~~68~~ in the manufacturing of medicament for ~~for use in~~ reducing ~~the~~ body-mass-index ~~of a subject~~.

~~72.~~73. Use of a ~~A~~ compound according to any one of Claims 1-68~~67~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 69~~68~~ in the manufacturing of medicament for ~~for use in~~ treating a metabolic disorder.

~~73.~~74. Use of a ~~A~~ compound according to any one of Claims 1-68~~67~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 69~~68~~ in the manufacturing of medicament for ~~for use in~~ treating a cardiovascular disorder.

~~74.~~75. Use of a ~~A~~ compound according to any one of Claims 1-68~~67~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 69~~68~~ in the manufacturing of medicament for ~~for use in~~ treating diabetes.

~~75.~~76. Use of a ~~A~~ compound according to any one of Claims 1-68~~67~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 69~~68~~ in the manufacturing of medicament for ~~for use in~~ treating obesity.

~~76.~~77. Use of a ~~A~~ compound according to any one of Claims 1-68~~67~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 69~~68~~ in the manufacturing of medicament for ~~for use in~~ treating dyslipidemia.

~~77.~~78. Use of a ~~A~~ compound according to any one of Claims 1-68~~67~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 69~~68~~ in the manufacturing of medicament for ~~for use in~~ treating non-alcoholic steatohepatitis (NASH).

~~78.~~79. Use of the compound according to any one of Claims 1-68~~67~~, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 69~~68~~ in the preparation of a medicament for one or more of reducing the body weight, reducing ~~or the~~ body-mass-index of a subject, treating obesity, treating a metabolic disorder, treating a cardiovascular disorder, treating diabetes, treating obesity, treating dyslipidemia, treating non-alcoholic steatohepatitis (NASH).

~~79. Use of the compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 68 in the preparation of a medicament for treating a metabolic or a cardiovascular disorder.~~


~~80. Use of the compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 68 in the preparation of a medicament for treating diabetes, obesity, dyslipidemia, or non-alcoholic steatohepatitis (NASH).~~

~~81. A method of reducing the body weight or the body mass index of a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.~~

~~82. A method of treating a metabolic or cardiovascular disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.~~

~~83. A method of treating diabetes, obesity, dyslipidemia, or non-alcoholic steatohepatitis (NASH) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.~~

~~84.~~80. A compound of Formula I-1



I-1

wherein

X is H or Br;

R^1 is O, S, or NH; and

R is H, F, Cl, -OH, -CN, –CO(C_{1-4}alkyl), –S(O)$_n$(C_{1-4}alkyl), -COOH, -COO(C_{1-4}alkyl), -CONH$_2$, -CONH(C_{1-4}alkyl), -CO(diC_{1-4}alkylamino), -NH(COC_{1-4}alkyl), -N(C_{1-4}alkyl)C(=O)F, C_{1-4}alkyl, -(CH$_2$)$_m$(C_{3-5}cycloalkyl), -CH$_2$(C_{3-5}heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}deuteroalkoxy, 5-membered heteroaryl, or 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, -NH_2, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -$S(O)_n(C_{1-4}$alkyl);

wherein the C_{1-4}alkoxy group is optionally substituted with 1 to 4 independently selected halogens or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, -NH_2, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -$S(O)_n(C_{1-4}$alkyl); and

wherein the -$CH_2(C_{3-5}$cycloalkyl), C_{3-4}heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkyl, -NH_2, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -$S(O)_n(C_{1-4}$alkyl).

~~85.~~81. The compound of Claim 80~~84~~, wherein X is H.

~~86.~~82. The compound of Claim 80~~84~~, wherein X is Br.


~~87.~~83. The compound of any one of Claims 80~~84~~-82~~86~~, wherein R^1 is O.

~~88.~~84. The compound of any one of Claims 80~~84~~-83~~87~~, wherein R is methyl.

~~89.~~85. The compound of any one of Claims 80~~84~~-83~~87~~, wherein R is methoxy.

~~90.~~86. The compound of any one of Claims 80~~84~~-83~~87~~, wherein R is hydroxymethyl.

~~91.~~87. A compound of Formula I-2



I-2

or a tautomer thereof, wherein

X is H or Br;

R^1 is O, S, or NH;

R is H, halogen, -OH, -CN, –CO(C_{1-4}alkyl), –S(O)$_n$(C_{1-4}alkyl), -COOH, -COO(C_{1-4}alkyl), -CONH$_2$, -CONH(C_{1-4}alkyl), -CO(diC_{1-4}alkylamino), -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, -NH(COC_{1-4}alkyl), -N(C_{1-4}alkyl)C(=O)F, C_{1-4}alkyl, -(CH$_2$)$_m$(C_{3-5}cycloalkyl), -CH$_2$(C_{3-5}heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}deuteroalkoxy, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl);

wherein the C_{1-4}alkoxy group is optionally substituted with 1 to 4 independently selected halogens or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl); and

wherein the -CH$_2$(C_{3-5}cycloalkyl), C_{3-4}heterocycloalkyl, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkyl, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl); and

R'' is H, 2-trimethylsilylethoxymethyl, -OH, –CO(C_{1-4}alkyl), –S(O)$_n$(C_{1-4}alkyl), -COO(C_{1-4}alkyl), -CONH$_2$, -CONH(C_{1-4}alkyl), -CO(diC_{1-4}alkylamino), C_{1-4}alkyl, -(CH$_2$)$_m$(C_{3-5}cycloalkyl), -CH$_2$(C_{3-5}heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, phenyl, 5-membered heteroaryl, or 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl); and

wherein the –(CH$_2$)$_m$(C_{3-5}cycloalkyl), C_{3-4}heterocycloalkyl, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkyl, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl);

with the proviso that if X is H and R'' is not 2-trimethylsilylethoxymethyl, then R is not H, $C_{1\text{-}4}$alkyl, or phenyl.

~~92.~~88. The compound of Claim 87~~91~~, or a tautomer thereof, wherein X is H.

~~93.~~89. The compound of Claim 87~~91~~, or a tautomer thereof, wherein X is Br.

~~94.~~90. The compound of any one of Claims 87~~91~~-89~~93~~, or a tautomer thereof, wherein R^1 is O.

~~95.~~91. The compound of any one of Claims 89~~93~~-90~~94~~, or a tautomer thereof, wherein R is H.

~~96.~~92. The compound of any one of Claims 89~~93~~-90~~94~~, or a tautomer thereof, wherein R is Cl.

~~97.~~93. The compound of any one of Claims 89~~93~~-90~~94~~, or a tautomer thereof, wherein R is hydroxymethyl.

~~98.~~94. The compound of any one of Claims 89~~93~~-90~~94~~, or a tautomer thereof, wherein R is methyl.

~~99.~~95. The compound of any one of Claims 87~~91~~-94~~98~~, or a tautomer thereof, wherein R'' is H.

~~100.~~96. The compound of any one of Claims 87~~91~~-94~~98~~, or a tautomer thereof, wherein R'' is methyl.

~~101.~~97. The compound of any one of Claims 87~~91~~-94~~98~~, or a tautomer thereof, wherein R'' is CD_3.

~~102.~~98. The compound of any one of Claims 87~~91~~-94~~98~~, or a tautomer thereof, wherein R'' is $-CH_2CH_2OH$.

~~103.~~99. The compound of any one of Claims 87~~91~~-94~~98~~, or a tautomer thereof, wherein R'' is -CH_2CN.

~~104.~~100. A compound, wherein the compound is 1-(2,2,3,3,3-pentafluoropropyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole.